A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified

Robyn Rexwinkel1, Arine M Vlieger2, Miguel Saps3

  • 1Emma Children's Hospital, Amsterdam UMC, Pediatric Gastroenterology, University of Amsterdam, Room C2-312, PO Box 22700, 1100 DD, Amsterdam, Netherlands. r.rexwinkel@amsterdamumc.nl.

Insights

Pediatric functional abdominal pain disorders like Irritable Bowel Syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) require a tailored, stepwise approach. Management involves shared decision-making with families on non-pharmacological and pharmacological treatments.

Area of Science:

  • Pediatric Gastroenterology
  • Gut-Brain Interaction Disorders

Background:

  • Irritable Bowel Syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) are prevalent in childhood, impacting quality of life and incurring significant socioeconomic costs.
  • Current management of these gut-brain interaction disorders is challenging due to a lack of high-quality intervention trials and international guidelines.

Purpose of the Study:

  • To provide an updated overview of therapeutic options for pediatric IBS or FAP-NOS.
  • To recommend evidence-based management strategies for these common functional abdominal pain disorders in children.

Main Methods:

  • This review synthesizes current knowledge on therapeutic possibilities for pediatric IBS and FAP-NOS.
  • It proposes a stepwise, individualized management approach based on patient-specific physical and psychological symptoms.

Main Results:

  • A positive diagnosis of IBS or FAP-NOS with minimal investigation is crucial to prevent unnecessary referrals and costs.
  • A tailor-made approach, considering both non-pharmacological and pharmacological interventions, is recommended.

Conclusions:

  • Shared decision-making with families is essential for managing pediatric functional abdominal pain disorders.
  • A stepwise, individualized strategy incorporating non-pharmacological and pharmacological interventions should be discussed with families.

Related Concept Videos

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
260
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
411
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
328
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
355
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
329
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
437